Souhaitez-vous accéder aux communiqués récents ?

Basel, Switzerland – June 18, 2025 - TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company developing TT125-802, a best-in-class CBP/p300 bromodomain inhibitor for the treatment of...

Berlin, Germany – June 17th, 2025 – Captain T Cell GmbH, a biotech company developing next-generation TCR-based cell therapies for patients with solid tumors, today announced that it has been selected...

- Deep and durable responses in drug-resistant KRAS-G12C- and EGFR-mutant NSCLC - Best-in-class safety profile highlights potential for development in combination to treat patients with...

Pasithea Therapeutics completes Cohort 6 enrollment and dosing in Phase 1 PAS-004 trial for MAPK-driven advanced cancers; full enrollment by 2025.

MDNA11 significantly expands a unique population of ‘stem-like’ CD8+ T cells that leads to more persistent and effective anti-tumor activity MDNA11 has shown durable single agent activity, with a...

COMMUNIQUÉ DE PRESSE | Paris, France - 3 décembre 2024 Smart Immune, société de biotechnologie en stade clinique, et CELLforCURE by SEQENS, entreprise de développement et de fabrication en...

PRESS RELEASE | Paris, France – December 3, 2024 Smart Immune, a clinical-stage biotechnology company, and CELLforCURE by SEQENS, a Contract Development and Manufacturing Organization (CDMO) for...

Apeiron Therapeutics (Apeiron), a precision oncology company leveraging state-of-the-art structural biology and AI-guided molecular modeling for drug disco

Turnstone reports third quarter 2024 financial results and provides recent business highlights

CMO Dr. Harald Haeske to present innovative approaches for combining ADCs with immune checkpoint inhibitors to enhance therapeutic efficacyOBT will also present insights on its target discovery...